HOOK Stock Price, Chart, Stats & News
HOOKIPA Pharma Inc. (HOOK) does not currently pay a dividend.
HOOK chart
Fundamentals
Gross margin | 100.00% |
Operating margin | -435.16% |
Pretax margin | -377.69% |
Net margin | -376.98% |
Effective tax rate | 0.19% |
ROA | -106.26% |
ROE | -120.58% |
D/E | 0.02x |
Interest coverage ratio | – |
HOOK valuation
P/E | – |
P/S | 0.89x |
P/B | 0.47x |
P/CF | -0.30x |
P/FCF | -0.29x |
P/OCF | -0.30x |
PEG | -0.01x |
EV multiple | -0.87x |
About
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company’s immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial.
Similar securities
Based on sector and market capitalization
